Novo Nordisk's (NVO) weight-loss drug Wegovy is being offered in smaller doses of a compounded version by online weight-loss tool Noom, Reuters reported Tuesday, citing senior company officials.
Noom's compounded semaglutide, the active ingredient in Wegovy, is being offered as part of a program personalized for patients, the report said.
Noom Chief Executive Geoff Cook said the move would not conflict with US regulations amid a crackdown on mass production of generic versions of Wegovy, the report said.
"There is a personalized, and there has always been a personalized, exception," Cook said.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.